Healthcare / Diagnostics & ResearchTaipei Exchange
$20.45
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-235.2M · quality 56.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$716M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-6.4%
↓Gross Margin
19.1%
↓Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.6%
FCF CAGR
—
FCF margin
-121.8%
FCF / Net income
3.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $193.1M · net income $-74.5M · FCF $-235.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $193.1M | $193.1M | $180.6M | $231.9M | $252.7M |
| Net Income | $-74.5M | $-74.5M | $-38.7M | $4.9M | $27.7M |
| EBITDA | $-19.3M | $-19.3M | $2.2M | $64.2M | $68.3M |
| EPS | — | — | -1.11 | 0.14 | 0.95 |
| Gross Margin | 19.1% | 19.1% | 20.8% | 33.6% | 41.2% |
| Operating Margin | -40.4% | -40.4% | -33.9% | -1.9% | 13.4% |
| Net Margin | -38.6% | -38.6% | -21.4% | 2.1% | 11.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.19 | 0.19 | 0.16 | 0.10 | 0.04 |
| Cash Flow | |||||
| Free Cash Flow | $-235.2M | $-235.2M | $-344.0M | $-19.4M | $28.9M |
| Returns | |||||
| ROE | -6.4% | -6.4% | -3.1% | 0.4% | 2.2% |
| Valuation | |||||
| P/E | — | — | — | 328.21 | — |
| EV/EBITDA | — | — | 293.15 | 12.88 | — |
| P/B | 0.62 | 0.62 | 0.79 | 1.29 | — |
| Growth & Yield | |||||
| Revenue Growth | 7.0% | 7.0% | -22.1% | -8.2% | — |
| EPS Growth | — | — | -892.9% | -85.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-15.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.11 → n/d
Residual
-15.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.